Potential mediators for treatment effects of novel diabetes medications on cardiovascular and renal outcomes: a meta‐regression analysis
JM Rodriguez‐Valadez, M Tahsin… - Journal of the …, 2024 - Am Heart Assoc
Background Prior research suggests clinical effects of glucagon‐like peptide‐1 receptor
agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are …
agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are …
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: a narrative review
AJ Scheen - Diabetes & Metabolism, 2023 - Elsevier
Abstract Background.-Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-
glucose cotransporter 2 inhibitors (SGLT2is), while developed as antihyperglycaemic …
glucose cotransporter 2 inhibitors (SGLT2is), while developed as antihyperglycaemic …
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
N Tamaki, SI Wakabayashi, T Kimura… - Hepatology …, 2024 - Wiley Online Library
Aims Optimizing glycemic control may prevent liver‐related events and major adverse
cardiovascular events (MACE) in patients with metabolic dysfunction‐associated steatotic …
cardiovascular events (MACE) in patients with metabolic dysfunction‐associated steatotic …
Efficacy and safety of Coccinia grandis (L.) Voigt on blood glucose and lipid profile: An updated systematic review and meta-analysis
W Phimarn, C Taengthonglang… - Journal of Herbmed …, 2024 - herbmedpharmacol.com
Introduction: Coccinia grandis has been shown to improve blood glucose and lipids. The
results of earlier clinical studies on the effects of C. grandis on blood sugar and lipid profile …
results of earlier clinical studies on the effects of C. grandis on blood sugar and lipid profile …
Stabilization of kidney function and reduction in heart failure events with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis and meta‐regression analysis
Aims Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors reduce the risk of heart failure
(HF) events regardless of diabetes status. However, factors associated with their efficacy in …
(HF) events regardless of diabetes status. However, factors associated with their efficacy in …
Agreement between mega-trials and smaller trials: a meta-research study
Importance: Mega-trials can provide large-scale evidence on important questions. Objective:
To explore how the results of mega-trails compare to the meta-analysis results of trials with …
To explore how the results of mega-trails compare to the meta-analysis results of trials with …
Mediators of Cardiovascular and Renal Outcomes: How Do Novel Diabetes Medications Work?
A Dakroub, ZI Almarzooq - Journal of the American Heart …, 2024 - Am Heart Assoc
Rodriguez-Valadez et al evaluated the mediators of GLP-1RAs and SGLT2is' clinical benefit
using 9 GLP-1RA and 13 SGLT2i trials. 6 These trials included adults with or without type 2 …
using 9 GLP-1RA and 13 SGLT2i trials. 6 These trials included adults with or without type 2 …
Implicações clínicas do uso de Inibidores de SGLT2 no manejo da insuficiência cardíaca
R de Almeida Benedito, TRP de Moraes… - Revista Eletrônica …, 2023 - acervomais.com.br
Objetivo: Avaliar as implicações clínicas do uso de inibidores de SGLT2 no manejo da
insuficiência cardíaca. Métodos: Por meio da plataforma de base de dados PubMed, foi …
insuficiência cardíaca. Métodos: Por meio da plataforma de base de dados PubMed, foi …
Correction: Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 …
Following the publication of the original article [1], the authors identified errors in Fig. 2
introduced during the final production phase. Specifically, the sample size numbers in the …
introduced during the final production phase. Specifically, the sample size numbers in the …